Clinical Trials Logo

Clinical Trial Summary

The main objective is to evaluate the efficacy and safety of treatment with 2 doses (80 and 160 mg) of Revacept versus placebo in patients with stable coronary artery disease undergoing PCI.


Clinical Trial Description

Revacept is a protein that is made up of an Fc fragment ("fragment crystallisable") fused to the GPVI receptor (the endogenous platelet collagen receptor). Consequently, Revacept binds to its ligand (collagen) on atherosclerotic plaques preventing circulating thrombocytes from binding to collagen exposed by the injured plaque. All this is achieved without affecting systemic hemostasis.

Thus, blocking of GPVI-dependent pathways by interfering with vascular collagen sites is commonly seen as an attractive target for an anti-platelet therapy of atherosclerotic diseases. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03312855
Study type Interventional
Source Deutsches Herzzentrum Muenchen
Contact
Status Completed
Phase Phase 2
Start date November 20, 2017
Completion date March 26, 2020

See also
  Status Clinical Trial Phase
Completed NCT01205425 - Computed Tomography Coronary Angiography Before Stent Implantation N/A
Completed NCT01243099 - Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions N/A
Completed NCT00642811 - A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders Phase 2
Recruiting NCT03089450 - To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent N/A
Completed NCT01523392 - A Pharmacodynamic Study With Ticagrelor in African American Patients Phase 4
Completed NCT01209637 - Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CAD N/A
Active, not recruiting NCT04434365 - Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease Phase 1/Phase 2
Completed NCT00510588 - Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease N/A
Completed NCT03384966 - A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease Phase 2
Active, not recruiting NCT01609465 - Prognostic Models for People With Stable Coronary Artery Disease N/A
Terminated NCT00911339 - Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents Phase 3
Completed NCT00984802 - Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy Phase 2
Completed NCT03782688 - Precise Percutaneous Coronary Intervention Plan (P3) Study
Completed NCT02580851 - Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention N/A
Recruiting NCT03313752 - Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity Phase 3
Completed NCT01184300 - ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation Phase 2/Phase 3
Completed NCT01523366 - A Pharmacodynamic Study With Ticagrelor in Hispanic Patients Phase 4
Completed NCT01118325 - An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease Phase 2
Recruiting NCT06123728 - MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease